



US007799536B2

(12) **United States Patent**
Dave et al.

(10) **Patent No.:** **US 7,799,536 B2**
(45) **Date of Patent:** **Sep. 21, 2010**

(54) **ENDOTHELIAL-MONOCYTE ACTIVATING
POLYPEPTIDE II, A BIOMARKER FOR USE
IN DIAGNOSIS OF BRAIN INJURY**

(75) Inventors: **Jitendra Ramanlal Dave**, Gaithersburg,
MD (US); **Changping Yao**,
Gaithersburg, MD (US); **Anthony
Joseph Williams**, Middletown, MD
(US); **Xi-Chun May**, Laurel, MD (US);
Frank Casper Tortella, Columbia, MD
(US); **Ka-Wang Kevin Wang**,
Gainesville, FL (US); **Ronald Lawrence
Hayes**, Gainesville, FL (US)

(73) Assignee: **The United States of America as
represented by the Secretary of the
Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/290,174**

(22) Filed: **Oct. 28, 2008**

(65) **Prior Publication Data**

US 2009/0068691 A1 Mar. 12, 2009

Related U.S. Application Data

(63) Continuation of application No. PCT/US2007/
011613, filed on May 15, 2007.

(60) Provisional application No. 60/809,986, filed on May
18, 2006.

(51) **Int. Cl.**
G01N 33/53 (2006.01)
G01N 33/567 (2006.01)
G01N 33/566 (2006.01)

(52) **U.S. Cl.** **435/7.92**; 435/7.21; 435/7.9;
436/501; 436/503

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO WO 2005/106038 A 11/2005

OTHER PUBLICATIONS

Mueller, et al., Lesional expression of a proinflammatory and
antiangiogenic cytokine EMP II confined to endothelium and
microglia/macrophages during secondary damage following experi-
mental traumatic brain injury, *J Neuroimmunol.*, vol. 135, No. 1-2,
Feb. 2003, pp. 1-9.

Brabeck, et al. Expression of EMAP II by activated monocytes,
microglial cells in different regions of hte rat hippocampus after
trimethyltin Induced brain damage., *Exp Neurol.*, vol. 177, No. 1 Sep.
2002, pp. 341-346.

Shalak, et al., The EMAPII cytokine is released from the mammalian
multisynthetase complex after cleavage of its p43/proEMAPII com-
ponent., *J Biol Chem*, vol. 276, No. 26, Jun. 2001, pp. 23769-23776.
Lee, et al., Penetrating brain injury leads to activation of ciliary
neurotrophic factor receptors, *Neurosci Lett*, vole 374, No. 3, Feb.
2005, pp. 161-165.

Choi, et al., Upregulation of gp130 and STAT 3 activation in the rat
hippocampus following transient forebrain ischemia, *GLIA*, bol. 41,
No. 3, Feb. 2003, pp. 237-246.

Gabbita, et al., Cleaved-tau, A biomarker of neuronal damage after
traumatic brain injury, *J Neurotrauma*, vol. 22, No. 1, Jan. 2005, pp.
83-94.

Database Medline [Online] US National Library of Medicine,
Bethesda, MD US, Nov. 2005, Siman et al., Novel surrogate markers
for acute brain damage: cerebrospinal fluid levels correlate with
seberity of ischemic neurodegeneration in the rat., XP002470879,
Database accession No. NLM15902199, cited in the appl. abstract &
J Cerebr Blood Flow Metabol, vol. 25, No. 11, Nov. 2005, pp. 1433-
1444.

Primary Examiner—Olga N Chernyshev

(74) *Attorney, Agent, or Firm*—Elizabeth Arwine

(57) **ABSTRACT**

A diagnostic tool and method of diagnosing brain injury and
brain injury type (traumatic vs. ischemic) by detecting the
level of expression of endothelial monocyte-activating
polypeptide II (EMAP-II) and comparing to a control. An
increase of EMAP-II indicates the presence of traumatic
brain injury and a decrease of EMAP-II indicates the pres-
ence of ischemic brain injury. Detection of EMAP-II can be
done in brain tissue, biofluids such as cerebrospinal fluid or
blood (including plasma and serum).

3 Claims, 9 Drawing Sheets